Altium Capital Management LLC Sells 124,743 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Altium Capital Management LLC decreased its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 35.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 230,257 shares of the biotechnology company's stock after selling 124,743 shares during the period. Altium Capital Management LLC owned approximately 0.18% of Arrowhead Pharmaceuticals worth $4,329,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in ARWR. Geode Capital Management LLC lifted its stake in Arrowhead Pharmaceuticals by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company's stock valued at $57,426,000 after acquiring an additional 26,171 shares in the last quarter. Norges Bank bought a new position in Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $38,622,000. Charles Schwab Investment Management Inc. grew its stake in shares of Arrowhead Pharmaceuticals by 1.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,017,720 shares of the biotechnology company's stock valued at $19,133,000 after buying an additional 10,785 shares in the last quarter. abrdn plc lifted its stake in Arrowhead Pharmaceuticals by 12.2% in the fourth quarter. abrdn plc now owns 450,075 shares of the biotechnology company's stock valued at $8,461,000 after acquiring an additional 48,929 shares during the last quarter. Finally, Privium Fund Management B.V. raised its holdings in shares of Arrowhead Pharmaceuticals by 14.2% in the 4th quarter. Privium Fund Management B.V. now owns 380,586 shares of the biotechnology company's stock valued at $7,155,000 after purchasing an additional 47,230 shares during the period. Institutional investors own 62.61% of the company's stock.

Wall Street Analysts Forecast Growth

ARWR has been the topic of a number of recent analyst reports. HC Wainwright reissued a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. B. Riley restated a "buy" rating and issued a $38.00 price target (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $42.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. Finally, Chardan Capital reiterated a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $41.44.

Insiders Place Their Bets

In other news, CEO Christopher Richard Anzalone sold 51,425 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $15.07, for a total value of $774,974.75. Following the completion of the transaction, the chief executive officer now directly owns 4,062,377 shares in the company, valued at approximately $61,220,021.39. The trade was a 1.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 276,839 shares of company stock worth $4,054,176 in the last 90 days. Company insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR stock traded up $0.61 on Wednesday, hitting $12.97. The company's stock had a trading volume of 743,308 shares, compared to its average volume of 1,436,785. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $9.57 and a fifty-two week high of $30.41. The company has a market capitalization of $1.78 billion, a PE ratio of -2.51 and a beta of 0.99. The stock's 50 day moving average is $14.99 and its 200-day moving average is $18.50. The company has a debt-to-equity ratio of 7.27, a quick ratio of 6.09 and a current ratio of 6.09.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last announced its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97). Equities research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.